Ruth O'Regan
Sponsored Research Projects
- A randomized, multicenter, double-blind phase 3 study of pd-0332991 (oral cdk 4/6 inhibitor) plus Letrozole versus placebo plus Letrozole for the treatment of postmenopausal women with ER (+), HER2 (-) breast cancer who have not received any prior
- DCFI Young & Strong: An Education & Supportive Care Intervention Study